Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs

• Published in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy biopharmaceuticals, and gene therapy, 2024-07, Vol.38 (4), p.511-526
• Main Authors: Sang, Angela, Zhuo, Selena, Bochanis, Adara, Manautou, José E., Bahal, Raman, Zhong, Xiao-bo, Rasmussen, Theodore P.
• Format: Article
• Language: English
• Subjects: Amino acid sequence; Amyloidosis; Amyotrophic lateral sclerosis; Animals; Antibodies; Antisense oligonucleotides; Antisense RNA; Antisense therapy; Biomedical and Life Sciences; Biomedicine; Cancer Research; Cytomegalovirus; Design; Drug Approval; Drug development; Duchenne's muscular dystrophy; FDA approval; Humans; Hypercholesterolemia; Molecular Medicine; mRNA; Mutation; Neuronal ceroid lipofuscinosis; Oligonucleotides, Antisense - pharmacology; Oligonucleotides, Antisense - therapeutic use; Pharmacotherapy; Review Article; Ribonuclease H; RNA Splicing - drug effects; RNA, Messenger - genetics; RNA, Messenger - metabolism; Spinal muscular atrophy; Transthyretin; United States; United States Food and Drug Administration; Yeast
• ISSN: 1173-8804; 1179-190X; 1179-190X
• DOI: 10.1007/s40259-024-00665-2

Antisense oligonucleotides (ASOs) are single stranded nucleic acids that target RNA. The US Food and Drug Administration has approved ASOs for several diseases. ASOs utilize three principal modes of action (MOA). The first MOA is initiated by base-pairing between the ASO and its target mRNA, followed by RNase H-dependent mRNA degradation. The second MOA is triggered by ASOs that occlude splice acceptor sites in pre-mRNAs leading to skipping of a mutation-bearing exon. The third MOA involves ASOs that sterically hinder mRNA function, often inhibiting translation. ASOs contain a variety of modifications to the sugar-phosphate backbone and bases that stabilize the ASO or render them resistant to RNase activity. RNase H-dependent ASOs include inotersen and eplontersen (for hereditary transthyretin amyloidosis), fomiversen (for opportunistic cytomegalovirus infection), mipomersen (for familial hypercholesterolemia), and tofersen [for amyotrophic lateral sclerosis (ALS)]. Splice modulating ASOs include nursinersen (for spinal muscular atrophy) and eteplirsen, golodirsen, viltolarsen, and casimersen (all for the treatment of Duchenne muscular dystrophy). In addition, a designer ASO, milasen, was used to treat a single individual afflicted with Batten disease. Since ASO design relies principally upon knowledge of mRNA sequence, the bench to bedside pipeline for ASOs is expedient compared with protein-directed drugs. [Graphical abstract available.] Graphical Abstract